CompletedPhase 2NCT00002943
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
Studying Extragonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- David D. Hurd, MDWake Forest University Health Sciences
- Intervention
- carboplatin(drug)
- Enrollment
- 11 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 1993 – 2007
Study locations (1)
- Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002943 on ClinicalTrials.govOther trials for Extragonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06418789High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell TumorsN.N. Petrov National Medical Research Center of Oncology
- RECRUITINGPHASE3NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02375204Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell TumorsAlliance for Clinical Trials in Oncology